LAWSUITS NEWS & LEGAL INFORMATION
Invokana and Invokamet Side Effects Legal News Articles & Interviews
December 22, 2017. By Anne Wallace.
Trenton, NJ: The pleasant-looking man looks into the camera and tells us that taking Invokana “may also help you lose a little weight.” Big problem. The FDA has not approved Invokana for weight-loss. The drug has had a rocky history since its approval in 2013, and a recent FDA warning cites the danger of Invokana leg and foot amputations. Direct-to-consumer drug advertising can magnify the harm that dangerous drugs do to patients who may spend more time listening to that friendly man (or his commercial kin) than they do talking with their own doctors.Read [ Invokana Amputation Lawsuits Cite Consumer Advertising ]
November 20, 2017. By Anne Wallace.
Trenton, NJ: The FDA warns of fracture risk with Invokana and Invokamet and more recently of a higher risk for foot and leg amputation. The lawsuit chickens have now come home to roost.Read [ Invokana Lawsuits Consolidated into MDL in New Jersey ]
August 8, 2017. By Gordon Gibb.
Washington, DC: A drug indicated for the treatment of type 2 diabetes already carries warnings for compelling adverse reactions including a heightened risk for lower limb amputations, kidney failure, diabetic ketoacidosis and cardiovascular injuries. To that end, the FDA warns of fracture risk with Invokana and Invokamet. Yet in spite of such serious side effects associated with Invokana (canagliflozin) and Invokamet (canagliflozin and metformin), the US Food and Drug Administration (FDA) approved, last year an expanded indication for Invokamet.Read [ Are Risk of Invokana and Invokamet Bone Fractures a Sign of Fractured Regulations? ]
June 13, 2017. By Gordon Gibb.
Boston, MA: A new study recently published in the New England Journal of Medicine (06/08/17) with regard to the potential for diabetic ketoacidosis (DKA) shows that type 2 diabetes patients on sodium-glucose cotransporter 2 (SGLT2) inhibitor drugs appear to have double the risk for DKA when compared with patients using dipeptidyl peptidase-4 (DPP-4) inhibitors. Invokana is a member of the SGLT2 class, and ample concern has been expressed over Invokana linked with cardiovascular injuries and kidney failure.Read [ Invokana Adverse Events Subject to Much Scrutiny ]
May 18, 2017. By Gordon Gibb.
Washington, DC: An issue that looms even larger than that of Invokana linked with cardiovascular injuries and kidney failure is the potential for amputation associated with the diabetes drug. The issue first surfaced a year ago when the US Food and Drug Administration (FDA) issued an alert after studying the results of two clinical trials, warning that users of Invokana and Invokamet were twice as likely to require amputations of appendages, or limbs.Read [ Invokana to Get Black-Box Warning over Amputation Risk ]
April 15, 2017. By Gordon Gibb.
Trenton, NJ: We’re coming up to the first anniversary of a health and safety review conducted by Health Canada in May, 2016 with regard to Sodium-glucose cotransporter-2 (SGLT2) inhibitors: Invokana (canagliflozin), Forxiga (dapagliflozin), and Jardiance (empagliflozin). The move followed a similar review and a warning by the US Food and Drug Administration (FDA) with regard to the potential for cardiovascular injuries and kidney failure.Read [ Invokana Lawsuits Keep Trickling In ]
March 8, 2017. By Gordon Gibb.
Philadelphia, PA: A series of complex legal arguments and maneuvering with regard to jurisdictional issues may have served to briefly divert attention away from Invokana adverse events. However, plaintiffs are nonetheless steeled in their resolve to pursue compensation amidst allegations over Invokana linked with cardiovascular injuries and kidney failure.Read [ Invokana Lawsuits Will Remain in Federal Court In Philadelphia ]
February 8, 2017. By Gordon Gibb.
Trenton, NJ: It was about a year ago that the European Medicines Agency (EMA) raised the alarm over kidney problems associated with diabetes medication Invokana and other drugs in the SGLT2 class. This followed a warning the previous year from the Institute for Safe Medication Practices, which reported in 2015 its identification of some 457 serious adverse events involving kidney failure or impairment. Dehydration and fluid imbalances, kidney stones, urinary tract infections and abnormal weight loss were also identified. That led to various headlines suggesting Invokana Linked with Cardiovascular Injuries and Kidney Failure.Read [ Invokana Still Invoking Concerns ]
January 3, 2017. By Heidi Turner.
Trenton, NJ: Plaintiffs involved in Invokana lawsuits are celebrating now that at least some lawsuits have been consolidated for pretrial proceedings. The Invokana claims were filed against drug maker Johnson & Johnson and allege the company failed adequately test the drug before releasing it on the market and did not warn consumers about the risks associated with using the diabetes medication.Read [ Plaintiffs Celebrate Invokana Lawsuit Consolidation ]
December 10, 2016. By Heidi Turner.
Charlotte, NC: On December 1, 2016, the US Judicial Panel on Multidistrict Litigation (JPML) considered consolidating Invokana lawsuits for pretrial proceedings. Although a decision has not been issued yet, a response to the motion for consolidation was filed by Janssen Pharmaceuticals and indicates the company is also in favor of consolidating the lawsuits.Read [ Judicial Panel Considers Consolidating Invokana Lawsuits ]
- Janssen Loses One Invokana Battle By Heidi Turner (Nov-11-16)